Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies
International Journal of Hypertension · 2026-01 · 2026 (1)
DOI: 10.1155/ijhy/9656975 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Hypertension, online erschienen am 14.07.2026. Verfasst von Yu Ra Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, 55365, South Korea, kfri.re.kr. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea National Institute of Health.
Abstract (Originalsprache)
Resistant hypertension (RH), defined as uncontrolled blood pressure despite the use of at least three optimally dosed antihypertensive agents, including a diuretic, remains a major clinical challenge associated with elevated cardiovascular risk. Metabolomics offers a dynamic approach to characterize biochemical perturbations related to amino acid metabolism, lipid remodeling, mitochondrial dysfunction, oxidative stress, renal impairment, and gut microbiota–derived metabolites. However, current evidence remains limited by small sample sizes, cross‐sectional designs, heterogeneous definitions of RH, inadequate exclusion of pseudoresistance, medication confounding, and limited external validation. This structured narrative review synthesizes RH‐specific metabolomic evidence and distinguishes it from findings extrapolated from broader hypertension populations. We further discuss methodological challenges, replication gaps, pharmacometabolomic confounding, and validation standards required for clinical implementation. Integrating metabolomics with clinical phenotyping, genomics, proteomics, and microbiome profiling may eventually support RH phenotyping, treatment–response prediction, and biomarker‐guided precision medicine, but large longitudinal cohorts with confirmed true RH are needed before clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Food Functionality Research Division, Korea Food Research Institute, Wanju-gun, Jeollabuk-do, 55365, South Korea, kfri.re.kr.
- Department of Biomedical Science, Hallym University, Chuncheon-si, Gangwon-do, 24252, South Korea, hallym.ac.kr.
- Department of Food Biotechnology, Korea National University of Science and Technology, Daejeon, 34113, South Korea.
ORCID-Profile: Yu Ra Lee, Yoon Shin Cho, Ho-Young Park
Förderung
- Korea National Institute of Health
Zitieren
APA
Lee, Y. R., Park, M., Cho, Y. S., & Park, H. Y. (2026). Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies. International Journal of Hypertension, 2026(1). https://doi.org/10.1155/ijhy/9656975
Vancouver
Lee YR, Park M, Cho YS, Park HY. Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies. International Journal of Hypertension. 2026;2026(1). doi:10.1155/ijhy/9656975
BibTeX
@article{Lee2026,
author = {Lee, Yu Ra and Park, Miri and Cho, Yoon Shin and Park, Ho-Young},
title = {Metabolomics and Precision Medicine in Resistant Hypertension: Pathophysiological Insights, Biomarker Discovery, and Translational Strategies},
journal = {International Journal of Hypertension},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijhy/9656975}
}
EUVIMED